Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility

RATIONALE: Cognitive impairment is a primary feature of many neuropsychiatric disorders and there is a need for new therapeutic options. Catechol-O-methyltransferase (COMT) inhibitors modulate cortical dopaminergic function and have been proposed as potential cognitive enhancers. Unfortunately, curr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Psychopharmacology (Berl)
Autors principals: Byers, Spencer, Buchler, Ingrid P., DePasquale, Michael, Rowley, Helen L., Kulkarni, Rajiv S., Pinder, Lucy, Kolobova, Anna, Li, Cailian, Au, Vinh, Akuma, Daniel, Zhang, Gongliang, Wei, Huijun, Cheetham, Sharon C., Barrow, James C., Carr, Gregory V.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790123/
https://ncbi.nlm.nih.gov/pubmed/32474681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-020-05566-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars